Surprisingly, patients in late clinical stages with low CES1 expression had better outcomes than those in early stages with high CES1 expression, indicating CES1’s significance as an independent prognostic factor in HNSCC. This evidence concerns the gene CES1 and head and neck squamous cell carcinoma.